Business Wire

UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy ...
KXAN

Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform ...

MUMBAI, India and NAPLES, Fla., Nov. 14, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of ...
Monthly Prescribing Reference

Preventing Relapse in Schizophrenia: Oral vs. Long-Acting Injectable Therapies

A recent report by Buckley et al analyzed a previous study to determine the differences in second and third relapse rates in patients receiving long-acting injectable risperidone versus an oral second ...
Nasdaq

Teva Pharmaceuticals Reports Positive Real-World Outcomes for UZEDY® (risperidone) in Schizophrenia Treatment Compared to Second-Generation Oral Antipsychotics

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...
Healio

FDA accepts NDA for subcutaneous risperidone injectable

Please provide your email address to receive an email when new articles are posted on . Teva Pharmaceuticals and MedinCell announced FDA acceptance of a new drug application for risperidone ...
Nasdaq

New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)

Switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provided the most comparable pharmacokinetic (PK) profile based on the relevant PK modeling data Additional ...
MedPage Today

Extended-Release Risperidone Injectable Staves Off Schizophrenia Relapse

An investigational long-acting antipsychotic containing risperidone, known as TV-46000, was able to significantly delay time to relapse in patients with schizophrenia, according to the phase III RISE ...
Medscape

FDA OKs Once-Monthly Risperidone Injection for Schizophrenia

The US Food and Drug Administration has approved the first once-monthly subcutaneous injection of risperidone (Perseris, Indivior) for the treatment of schizophrenia in adults. Perseris uses an ...
Medscape

Long-Acting Risperidone Injection

Purpose: The pharmacology, pharmaceutics, clinical efficacy, adverse effects, cost, and dosage and administration of long-acting risperidone injection are reviewed. Summary: Risperidone is the first ...
Monthly Prescribing Reference

Additional injection site approved for Risperdal Consta

The FDA has approved the injection of Risperdal Consta (risperidone long-acting injection, from Janssen) into the deltoid muscle of the arm for the treatment of schizophrenia. This approval was based ...
Business Wire

Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia

TEL AVIV, Israel & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals Industries Ltd. (NYSE and TASE: TEVA) and MedinCell (Euronext: MEDCL) today announced positive results for study TV46000-CNS-30072 (the ...